Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma.
CONCLUSIONS: Targeted therapies, lenvatinib and dabrafenib plus trametinib (for BRAF V600E mutants), may provide clinical benefit in ATC patients who are unable to participate in clinical trials, with manageable toxicities.
PMID: 29161986 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Endocrinology | Study | Thyroid | Thyroid Cancer | Toxicology